** Hong Kong shares of vaccine producer CanSino Biologics Inc 6185.HK jump 7% to HK$32.20, their highest since Jan. 6, and on track for sixth straight session of gain
** Stock on track for the biggest one-day pct gain since Nov. 11, 2024
** Shanghai-listed stock 688185.SS climbs 3.5% to 63.66 yuan, high since Dec. 31, 2024
** CanSino said China's National Medical Products Administration (NMPA) granted priority review status to the firm's new drug application (NDA) for its absorbed diphtheria, tetanus and acellular pertussis combined vaccine for infants below 2 years
** NMPA will prioritize resource allocation for the review of NDAs, included in the scope of priority review and approval - co
** Hong Kong's healthcare index .HSCIH rises 1.4%, Hang Seng Index .HSI surges 1.7%
** Hong Kong stock rose 33.8% last year, while Shanghai-listed shares fell 18.1%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。